Evidence map›Paper›PMID 37061918›Full record

ArticleCell reports2023

Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.

Bronwyn M Gunn, Ryan P McNamara, Lianna Wood, Sabian Taylor, Anush Devadhasan, Wenyu Guo, Jishnu Das, Avlant Nilsson, Amy Shurtleff, Sheri Dubey and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Machine Learning in Nonhuman Primate Models of Infectious Diseases: Current Applications and Future Perspectives.Journal of the American Association for Laboratory Animal Science : JAALAS · 2026
    Review
  2. CD4Nature immunology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Bronwyn M GunnRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ryan P McNamaraRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Electronic address: ragonsystemserology@mgh.harvard.edu.
Lianna WoodRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Division of Gastroenterology, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Sabian TaylorRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Anush DevadhasanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Wenyu GuoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Jishnu DasRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Avlant NilssonDivision of Gastroenterology, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Amy ShurtleffUnited States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Sheri DubeyMerck & Co., Inc., Kenilworth, NJ, USA.
Michael EichbergMerck & Co., Inc., Kenilworth, NJ, USA.
Todd J SuscovichRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Erica Ollmann SaphireLa Jolla Institute for Immunology, La Jolla, CA, USA.
Douglas LauffenburgerDivision of Gastroenterology, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
Beth-Ann CollerMerck & Co., Inc., Kenilworth, NJ, USA.
Jakub K SimonMerck & Co., Inc., Kenilworth, NJ, USA.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Ragon Institute of MGH, MIT and Harvard · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USBoston Children's Hospital · USLa Jolla Institute for Immunology · USMassachusetts Institute of Technology · USUnited States Army Medical Research Institute of Infectious Diseases · US

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0M
NIAID NIH HHS U19 AI135995NIAID NIH HHS U19 AI142790
6 · The paper itself

Abstract

The 2013 Ebola epidemic in Central and West Africa heralded the emergence of wide-spread, highly pathogenic viruses. The successful recombinant vector vaccine against Ebola (rVSVΔG-ZEBOV-GP) will limit future outbreaks, but identifying mechanisms of protection is essential to protect the most vulnerable. Vaccine-induced antibodies are key determinants of vaccine efficacy, yet the mechanism by which vaccine-induced antibodies prevent Ebola infection remains elusive. Here, we exploit a break in long-term vaccine efficacy in non-human primates to identify predictors of protection. Using unbiased humoral profiling that captures neutralization and Fc-mediated functions, we find that antibodies specific for soluble glycoprotein (sGP) drive neutrophil-mediated phagocytosis and predict vaccine-mediated protection. Similarly, we show that protective sGP-specific monoclonal antibodies have elevated neutrophil-mediated phagocytic activity compared with non-protective antibodies, highlighting the importance of sGP in vaccine protection and monoclonal antibody therapeutics against Ebola virus.

Indexed as

Ebola VaccinesEbolavirusHemorrhagic Fever, EbolaAnimalsAntibodies, MonoclonalAntibodies, ViralGlycoproteinsPrimatesVaccines, SyntheticAntibodies, MonoclonalAntibodies, ViralEbola VaccinesGlycoproteinsVaccines, SyntheticADNPantibodiesCP: ImmunologyEbolaglycoproteinsoluble glycoproteinvaccine

Identifiers

PMID37061918
PMCPMC10576837
OpenAlexW4365815942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.